PropertyValue
?:abstract
  • More than a million people have now died from COVID-19, because of infection with the SARS-CoV-2 coronavirus. Currently, the FDA has approved remdesivir, an inhibitor of SARS-CoV-2 replication, to treat COVID-19, though very recent data from WHO showed little if any COVID19 protective effect. Here we report that ethacridine, a safe and potent antiseptic use in humans, effectively inhibits SARS-CoV-2, at very low concentrations (EC(50) ~ 0.08 μM). Ethacridine was identified through a high-throughput screening of an FDA-approved drug library in living cells using a fluorescent assay. Interestingly, the main mode of action of ethacridine is to inactivate virus particles, preventing binding to the host cells. Thus, our work has identified a potent drug with a distinct mode of action against SARS-CoV-2.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1101/2020.10.28.359042
?:journal
  • bioRxiv
?:license
  • cc-by-nc-nd
?:pdf_json_files
  • document_parses/pdf_json/30179b8935aaf9b97a5125eadbbbdf94a8ccba4b.json; document_parses/pdf_json/c790c4b68521423238e0f5c02b89e95cb2d9e932.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7605555.xml.json
?:pmcid
?:pmid
?:pmid
  • 33140048.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • BioRxiv; Medline; PMC; WHO
?:title
  • Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models
?:type
?:year
  • 2020-10-28

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/ek8j5rpx>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/ek8j5rpx>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all